Market revenue in 2021 | USD 3,566.6 million |
Market revenue in 2030 | USD 4,885.7 million |
Growth rate | 3.6% (CAGR from 2021 to 2030) |
Largest segment | Mammalian |
Fastest growing segment | Non-mammalian |
Historical data | 2017 - 2020 |
Base year | 2021 |
Forecast period | 2022 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Mammalian, Non-mammalian |
Key market players worldwide | Boehringer Ingelheim, Lonza Group Ltd, Innovent Biologics Inc, Rentschler Biopharma SE, JRS Pharma, AGC Inc, Probiogen, FUJIFILM Holdings Corp, Toyobo Co Ltd, Samsung BioLogics, Thermo Fisher Scientific Inc, R1 RCM Inc, WuXi Biologics (Cayman) Inc, AbbVie Inc, Binex, Charles River Laboratories International Inc, Icon PLC, PAREXEL, Labcorp Holdings Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to biopharmaceutical cmo and cro market will help companies and investors design strategic landscapes.
Mammalian was the largest segment with a revenue share of 54.91% in 2021. Horizon Databook has segmented the China biopharmaceutical cmo and cro market based on mammalian, non-mammalian covering the revenue growth of each sub-segment from 2017 to 2030.
This country is expected to benefit significantly by the local presence of prominent market leaders. For instance, in December 2018, Lonza signed an agreement with GE Healthcare, as per the agreement GE Healthcare provided a biologics manufacturing facility of Lonza to support the manufacturing of biopharmaceuticals in the country.
Increase in outsourcing of operations to Chinese market players by overseas biopharma firms is recognized as the major driver for the Chinese CMO & CRO market. Global innovator companies outsource a significant portion of their research to restructure R&D and cut costs.
Furthermore, biotechnology and its related aspects are significantly funded by the Chinese government. Regulatory changes to enhance safe & effective usage and rapid development of drugs in China are expected to positively influence the market growth.
Horizon Databook provides a detailed overview of country-level data and insights on the China biopharmaceutical cmo and cro market , including forecasts for subscribers. This country databook contains high-level insights into China biopharmaceutical cmo and cro market from 2017 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account